Pharmacological targeting of β-adrenergic receptor functions abrogates NF-κB signaling and MMP-9 secretion in medulloblastoma cells

OncoTargets and Therapy

Volumn 3, Issue , 2010, Pages 219-226

  Annabi, Borhane ^a   Vaillancourt Jean, Eric ^a   Weil, Alexander G ^c   Béliveau, Richard ^b,c  

^a Centre de Recherche BioMED   (Canada)

^b UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

adrenergic receptors; Medulloblastoma; MMP 9; NF B

Indexed keywords

BETA ADRENERGIC RECEPTOR; GELATINASE B; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHORBOL 13 ACETATE 12 MYRISTATE; PROPRANOLOL;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; CANCER CELL CULTURE; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG TARGETING; ENZYME DEGRADATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME RELEASE; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; IN VITRO STUDY; MEDULLOBLASTOMA; NUCLEOTIDE SEQUENCE; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 84859148054     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S14503     Document Type: Article

References (50)

1. Shigemori Y, Katayama Y, Mori T, Maeda T, Kawamata T. Matrix metalloproteinase-9 is associated with blood-brain barrier opening and brain edema formation after cortical contusion in rats. Acta Neurochir Suppl. 2006;96:130-133.
2. Jadhav U, Chigurupati S, Lakka SS, Mohanam S. Inhibition of matrix metalloproteinase-9 reduces in vitro invasion and angiogenesis in human microvascular endothelial cells. Int J Oncol. 2004;25: 1407-1414.
3. Ahn GO, Brown JM. Matrix metalloproteinase-9 is required for tumour vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer Cell. 2008;13:193-205.
4. Boscolo E, Bischoff J. Vasculogenesis in infantile hemangioma. Angiogenesis. 2009;12:197-207.
5. Kleinman ME, Greives MR, Churgin SS, et al. Hypoxia-induced mediators of stem/progenitor cell traff icking are increased in children with hemangioma. Arterioscler Thromb Vasc Biol. 2007;27: 2664-2670.
6. Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taïeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358:2649-2651.
7. Siegfried EC, Keenan WJ, Al-Jureidini S. More on propranolol for hemangiomas of infancy. N Engl J Med. 2008;359:2846; author reply 2846-2847.
8. Annabi B, Rojas-Sutterlin S, Laroche M, Lachambre MP, Moumdjian R, Béliveau R. The diet-derived sulforaphane inhibits matrix metalloproteinase- 9-activated human brain microvascular endothelial cell migration and tubulogenesis. Mol Nutr Food Res. 2008;52:692-700.
9. Roomi MW, Monterrey JC, Kalinovsky T, Rath M, Niedzwiecki A. Distinct patterns of matrix metalloproteinase-2 and -9 expression in normal human cell lines. Oncol Rep. 2009;21:821-826.
10. Sina A, Lord-Dufour S, Annabi B. Cell-based evidence for aminopeptidase N/CD13 inhibitor actinonin targeting of MT1-MMP-mediated proMMP-2 activation. Cancer Lett. 2009;279:171-176.
11. Abécassis I, Olofsson B, Schmid M, Zalcman G, Karniguian A. RhoA induces MMP-9 expression at CD44 lamellipodial focal complexes and promotes HMEC-1 cell invasion. Exp Cell Res. 2003;291: 363-376.
12. Demeule M, Régina A, Annabi B, Bertrand Y, Bojanowski MW, Béliveau R. Brain endothelial cells as pharmacological targets in brain tumours. Mol Neurobiol. 2004;30:157-183.
13. Annabi B, Rojas-Sutterlin S, Laflamme C, et al. Tumour environment dictates medulloblastoma cancer stem cell expression and invasive phenotype. Mol Cancer Res. 2008;6:907-916.
14. Annabi B, Currie JC, Moghrabi A, Béliveau R. Inhibition of HuR and MMP-9 expression in macrophage-differentiated HL-60 myeloid leukemia cells by green tea polyphenol EGCg. Leuk Res. 2007;31:1277-1284.
15. Higashida T, Kreipke CW, Rafols JA, et al. The role of hypoxiainducible factor-1alpha, aquaporin-4, and matrix metalloproteinase-9 in blood-brain barrier disruption and brain edema after traumatic brain injury. J Neurosurg. In press 2010.
16. Tsuge M, Yasui K, Ichiyawa T, et al. Increase of tumour necrosis factor-alpha in the blood induces early activation of matrix metalloproteinase- 9 in the brain. Microbiol Immunol. 2010;54:417-424.
17. Dong J, Jimi E, Zeiss C, Hayden MS, Ghosh S. Constitutively active NF-kappaB triggers systemic TNFalpha-dependent inflammation and localized TNFalpha-independent inflammatory disease. Genes Dev. 2010;24:1709-1717.
18. Solt LA, May MJ. The IkappaB kinase complex: master regulator of NF-kappaB signalling. Immunol Res. 2008;42:3-18.
19. Agarwal R, Agarwal C, Ichikawa H, Singh RP, Aggarwal BB. Anticancer potential of silymarin: from bench to bed side. Anticancer Res. 2006;26:4457-4498.
20. Shioda N, Han F, Fukunaga K. Role of Akt and ERK signalling in the neurogenesis following brain ischemia. Int Rev Neurobiol. 2009;85:375-387.
21. Burkhard K, Smith S, Deshmukh R, MacKerell AD Jr, Shapiro P. Development of extracellular signal-regulated kinase inhibitors. Curr Top Med Chem. 2009;9:678-689.
22. Dillon RL, Muller WJ. Distinct biological roles for the akt family in mammary tumour progression. Cancer Res. 2010;70:4260-4264.
23. Emilien G, Maloteaux JM. Current therapeutic uses and potential of beta-adrenoceptor agonists and antagonists. Eur J Clin Pharmacol. 1998;53:389-404.
24. Benish M, Bartal I, Goldfarb Y, et al. Perioperative use of betablockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumour metastasis. Ann Surg Oncol. 2008;15: 2042-2052.
25. Park PG, Merryman J, Orloff M, Schuller HM. Beta-adrenergic mitogenic signal transduction in peripheral lung adenocarcinoma: implications for individuals with preexisting chronic lung disease. Cancer Res. 1995;55:3504-3508.
26. Annabi B, Lachambre MP, Plouffe K, Moumdjian R, Béliveau R. Propranolol adrenergic blockade inhibits human brain endothelial cells tubulogenesis and matrix metalloproteinase-9 secretion. Pharmacol Res. 2009;60:438-445.
27. Yang EV, Sood AK, Chen M, et al. Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumour cells. Cancer Res. 2006;66:10357-10364.
28. Al-Wadei HA, Al-Wadei MH, Schuller HM. Prevention of pancreatic cancer by the beta-blocker propranolol. Anticancer Drugs. 2009; 20:477-482.
29. Palm D, Lang K, Niggemann B, et al. The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by beta-blockers. Int J Cancer. 2006;118: 2744-2749.
30. Wang H, Cho CH. Effect of NF-κB signalling on apoptosis in chronic inflammation-associated carcinogenesis. Curr Cancer Drug Targets. 2010;10:593-599.
31. Tak PP, Firestein GS. NF-kappaB: a key role in inflammatory diseases. J Clin Invest. 2001;107:7-11.
32. Moon DO, Kim MO, Kang SH, Choi YH, Kim GY. Sulforaphane suppresses TNF-alpha-mediated activation of NF-kappaB and induces apoptosis through activation of reactive oxygen species-dependent caspase-3. Cancer Lett. 2009;274:132-142.
33. Sen T, Dutta A, Chatterjee A. Epigallocatechin-3-gallate (EGCG) downregulates gelatinase-B (MMP-9) by involvement of FAK/ERK/ NFkappaB and AP-1 in the human breast cancer cell line MDA-MB-231. Anticancer Drugs. 2010;21:632-644.
34. Farabegoli F, Papi A, Orlandi M. -(-)Epigallocatechin-3-gallate downregulates EGFR, MMP-2, MMP-9 EMMPRIN and inhibits the invasion of MCF-7 tamoxifen resistant cells. Biosci Rep. In press 2010.
35. Bangaru ML, Chen S, Woodliff J, Kansra S. Curcumin (diferuloylmethane) induces apoptosis and blocks migration of human medulloblastoma cells. Anticancer Res. 2010;30:499-504.
36. Yu YM, Lin HC. Curcumin prevents human aortic smooth muscle cells migration by inhibiting of MMP-9 expression. Nutr Metab Cardiovasc Dis. 2010;20:125-132.
37. Bedirli A, Salman B, Pasaoglu H, Ofluoglu E, Sakrak O. Effects of Nuclear Factor-kappaB Inhibitors on Colon Anastomotic Healing in Rats. J Surg Res. In press 2010.
38. Liu PL, Tsai JR, Charles AL, et al. Resveratrol inhibits human lung adenocarcinoma cell metastasis by suppressing heme oxygenase 1-mediated nuclear factor-kappaB pathway and subsequently downregulating expression of matrix metalloproteinases. Mol Nutr Food Res. 2010;54:S196-S204.
39. Déziel BA, Patel K, Neto C, Gottschall-Pass K, Hurta RA. Proanthocyanidins from the american cranberry (vaccinium macrocarpon) inhibit matrix metalloproteinase-2 and matrix metalloproteinase-9 activity in human prostate cancer cells via alterations in multiple cellular signalling pathways. J Cell Biochem. 2010;111:742-754.
40. Hwang ES, Lee HJ. Inhibitory effects of lycopene on the adhesion, invasion, and migration of SK-Hep1 human hepatoma cells. Exp Biol Med (Maywood). 2006;231:322-327.
41. Ralhan R, Pandey MK, Aggarwal BB. Nuclear factor-kappa B links carcinogenic and chemopreventive agents. Front Biosci (Schol Ed). 2009;1:45-60.
42. St-Pierre Y, Couillard J, van Themsche C. Regulation of MMP-9 gene expression for the development of novel molecular targets against cancer and inflammatory diseases. Expert Opin Ther Targets. 2004;8:473-489.
43. Chambard JC, Lefloch R, Pouysségur J, Lenormand P. ERK implication in cell cycle regulation. Biochim Biophys Acta. 2007;1773: 1299-1310.
44. Gervais M, Dugourd C, Muller L, et al. Akt down-regulates ERK1/2 nuclear localization and angiotensin II-induced cell proliferation through PEA-15. Mol Biol Cell. 2006;17:3940-3951.
45. Desrosiers RR, Rivard ME, Grundy PE, Annabi B. Decrease in LDL receptor-related protein expression and function correlates with advanced stages of Wilms tumors. Pediatr Blood Cancer. 2006;46: 40-49.
46. Jin R, Yang G, Li G. Molecular insights and therapeutic targets for blood-brain barrier disruption in ischemic stroke: critical role of matrix metalloproteinases and tissue-type plasminogen activator. Neurobiol Dis. 2010;38:376-385.
47. Annabi B, Doumit J, Plouffe K, Laflamme C, Lord-Dufour S, Béliveau R. Members of the low-density lipoprotein receptor-related proteins provide a differential molecular signature between parental and CD133+ DAOY medulloblastoma cells. Mol Carcinog. 2010;49:710-717.
48. Weiswald LB, Richon S, Validire P, et al. Newly characterised ex vivo colospheres as a three-dimensional colon cancer cell model of tumour aggressiveness. Br J Cancer. 2009;101:473-482.
49. Zhang D, Ma QY, Hu HT, Zhang M. beta2-adrenergic antagonists suppress pancreatic cancer cell invasion by inhibiting CREB, NFkappaB and AP-1. Cancer Biol Ther. 2010;10:19-29.
50. Romana-Souza B, Santos JS, Monte-Alto-Costa A. beta-1 and beta-2, but not alpha-1 and alpha-2, adrenoceptor blockade delays rat cutaneous wound healing. Wound Repair Regen. 2009;17:230-239.